Current Report Filing (8-k)
May 16 2013 - 5:00PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date Of Report (Date Of Earliest Event Reported):
May 16, 2013
NORTHWEST BIOTHERAPEUTICS, INC. |
(Exact Name of Registrant as Specified in Its Charter) |
Delaware |
|
0-33393 |
|
94-3306718 |
(State Or Other Jurisdiction Of Incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer Identification No.) |
___4800 Montgomery Lane, Suite 800, Bethesda,
MD 20814 ___
(Address Of Principal Executive Offices) (Zip Code)
Registrant’s Telephone Number, Including
Area Code (240) 497-9024
Check the appropriate box below if the Form 8-K is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On May 16, 2013, Northwest Biotherapeutics,
Inc. (the “Company”) issued a press release announcing that its Phase III clinical trial with DCVax-L for brain cancer
has been initiated at King’s College Hospital in the UK. A copy of the press release is included as Exhibit 99.1 to this
Current Report on Form 8-K. The trial was initiated at King’s on May 10, 2013.
The information disclosed under this Item 8.01,
including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18
of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or
other document pursuant to the Securities Act of 1933, as amended, except as expressly set forth in such filing.
Item 9.01 Financial Statements and Exhibits
| 99.1 | Press Release of Northwest Biotherapeutics, Inc. dated
May 16, 2013. |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
NORTHWEST BIOTHERAPEUTICS, INC |
|
|
|
|
|
|
Dated: May 16, 2013 |
By: |
/s/ Linda Powers |
|
|
Name: Linda Powers |
|
|
Title: Chief Executive Officer and Chairman |
|
|
|
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Jul 2024 to Aug 2024
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Aug 2023 to Aug 2024